Table 2.
Number (%) of Patients Receiving Anticancer Drugs Received During the Peri-Index Period.
| Commercial (N = 572) | Medicare (N = 94) | Combined (N = 666) | |
|---|---|---|---|
| Number of specific anti-cancer medications received | |||
| 0 | 68 (11.9) | 26 (27.7) | 94 (14.1) |
| 1 | 380 (66.4) | 52 (55.3) | 432 (64.9) |
| 2 | 106 (18.5) | 13 (13.8) | 119 (17.9) |
| 3 | 17 (3.0) | 2 (2.1) | 19 (2.9) |
| 4+ | 1 (0.2) | 1 (1.1) | 2 (0.3) |
| Anticancer drugs received (any combination) | |||
| Capecitabine | 376 (65.7) | 41 (43.6) | 417 (62.6) |
| Paclitaxel | 21 (3.7) | 6 (6.4) | 27 (4.1) |
| Docetaxel | 7 (1.2) | 1 (1.1) | 8 (1.2) |
| Anthracyclines | 4 (0.7) | 0 (0.0) | 4 (0.6) |
| Vinorelbine | 21 (3.7) | 3 (3.2) | 24 (3.6) |
| Gemcitabine | 15 (2.6) | 3 (3.2) | 18 (2.7) |
| Any hormonal therapy | 59 (10.3) | 9 (20.2) | 68 (10.2) |
| Trastuzumab | 123 (21.5) | 19(20.2) | 142 (21.3) |
| Other chemotherapy | 17 (3.0) | 4 (4.3) | 21 (3.2) |
| Specific anticancer drug combinations received | |||
| None | 68 (11.9) | 26 (27.7) | 94 (14.1) |
| Capecitabine | 297 (51.9) | 31 (33.0) | 328 (49.2) |
| Trastuzumab | 41 (7.2) | 8 (8.5) | 49 (7.4) |
| Capecitabine + trastuzumab | 40 (7.0) | 5 (5.3) | 45 (6.8) |
| Capecitabine + hormone therapy | 20 (3.5) | 1 (1.1) | 21 (3.2) |
| Hormone therapy | 15 (2.6) | 5 (5.3) | 20 (3.0) |
| Taxane | 11 (1.9) | 2 (2.1) | 13 (2.0) |
| Trastuzumab + hormone therapy | 11 (1.9) | 1 (1.1) | 12 (1.8) |
| Capecitabine + trastuzumab + vinorelbine | 6 (1.0) | 0 (0.0) | 6 (0.9) |
| Vinorelbine | 6 (1.0) | 2 (2.1) | 8 (1.2) |
| Gemcitabine | 6 (1.0) | 2 (2.1) | 8 (1.2) |
| Trastuzumab + taxane | 8 (1.4) | 1 (1.1) | 9 (1.4) |
| Other | 43 (7.5) | 10 (10.6) | 53 (8.0) |